Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C

Gordon, A, Hobbs, D, Bowden, S, Bailey, M, Mitchell, J, Francis, A and Roberts, S 2006, 'Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C', Journal of Gastroenterology and Hepatology, vol. 21, pp. 275-280.


Document type: Journal Article
Collection: Journal Articles

Title Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C
Author(s) Gordon, A
Hobbs, D
Bowden, S
Bailey, M
Mitchell, J
Francis, A
Roberts, S
Year 2006
Journal name Journal of Gastroenterology and Hepatology
Volume number 21
Start page 275
End page 280
Total pages 6
Publisher Blackwell Publishing
Abstract BACKGROUND/AIMS - Silybum marianum is a herbal preparation commonly used by subjects with chronic hepatitis C (CHIC). The aims of this pilot study were to assess the efficacy and safety of S. marianum on serum hepatitis C virus (HCV) RNA, alanine aminotransferase levels and well-being in patients with CHC. METHODS - Twenty-four subjects with CHIC were enrolled into a randomized, double-blind, placebo-controlled, crossover study. Subjects received 12 weeks of S. marianum (either 600 mg or 1200 mg/day) and placebo separated by a 4-week washout interval. Baseline biochemical, virological, psychological and quality-of-life tests were performed, with biochemical tests repeated monthly, and HCV RNA titer and quality-of-life and psychological assessments repeated at the end of both treatment periods. RESULTS - Seventeen patients completed the trial. Mean changes in HCV RNA titers, serum ALT levels and Short Form-36 scores were not significantly different for subjects on S. marianum compared to those on placebo. There was no significant change in mean State-Trait Anxiety Inventory State-Anxiety scores on S. marianum from baseline. Adverse events were similar with S. marianum and placebo. CONCLUSIONS - S. marianum is well tolerated in subjects with CHC, but does significantly affect serum HCV RNA, alanine aminotransferase levels, quality of life or psychological well-being in subjects with this condition.
Keyword(s) Quality-Of-Life
Double-Blind
Liver
Silymarin
Infection
Cirrhosis
DOI - identifier 10.1111/j.1440-1746.2006.04138.x
Copyright notice © 2006 Blackwell Publishing Asia Pty Ltd.
ISSN 0815-9319
Versions
Version Filter Type
Citation counts: Scopus Citation Count Cited 69 times in Scopus Article | Citations
Altmetric details:
Access Statistics: 75 Abstract Views  -  Detailed Statistics
Created: Fri, 07 Jan 2011, 09:11:00 EST by Catalyst Administrator
© 2014 RMIT Research Repository • Powered by Fez SoftwareContact us